Marshall Wace
MRTX

Marshall Wace’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Marshall Wace’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-147,144
Closed -$6.41M – 2716
2023
Q3 		$6.41M Sell
147,144
-437,179
-75% -$15.6M 0.01% 786
2023
Q2 		$21.1M Buy
584,323
+31,709
+6% +$1.31M 0.04% 465
2023
Q1 		$20.5M Buy
+552,614
New +$24.9M 0.04% 461
2022
Q1 		– Sell
-83,364
Closed -$12.2M – 4220
2021
Q4 		$12.2M Buy
83,364
+43,132
+107% +$6.7M 0.02% 728
2021
Q3 		$7.12M Sell
40,232
-4,470
-10% -$719K 0.03% 752
2021
Q2 		$7.22M Sell
44,702
-2,842
-6% -$456K 0.03% 639
2021
Q1 		$8.14M Sell
47,544
-323,062
-87% -$64M 0.04% 559
2020
Q4 		$81.4M Sell
370,606
-57,793
-13% -$12.5M 0.44% 40
2020
Q3 		$71.1M Buy
+428,399
New +$58.6M 0.46% 42
2020
Q1 		– Sell
-7,482
Closed -$964K – 2160
2019
Q4 		$964K Buy
+7,482
New +$722K 0.01% 995
2019
Q2 		– Sell
-4,853
Closed -$356K – 1955
2019
Q1 		$356K Buy
4,853
+4,653
+2,327% +$317K ﹤0.01% 1227
2018
Q4 		$8K Buy
+200
New +$7.97K ﹤0.01% 1540
2018
Q2 		– Sell
-8,740
Closed -$268K – 877
2018
Q1 		$268K Buy
+8,740
New +$243K 0.01% 483

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Marshall Wace's MRTX Position: Q4 2023 in Review

Marshall Wace sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 147,144 shares — an estimated $6.41M sold.

Marshall Wace first reported a position in MRTX in Q1 2018 and held it in 13 quarters. The position peaked at $81.4M in Q4 2020. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Marshall Wace reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Marshall Wace sold 147,144 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $6.41M.
  • Marshall Wace first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2018 and held it in 13 quarters.
  • Marshall Wace's Mirati Therapeutics, Inc. Common Stock position peaked at $81.4M in Q4 2020.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Marshall Wace's 13F filing for Q4 2023, filed 14 Feb 2024.